EyePoint (EYPT) Receivables (2011 - 2026)
EyePoint (EYPT) posted Receivables of $1.2 million for Q1 2026, up 77.73% sequentially from $651000.0 in Q4 2025, and up 161.76% YoY from $442000.0 in Q1 2025.
EyePoint (EYPT) Receivables (2011 - 2026) Analysis & Trends
EyePoint has reported Receivables for 16 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Receivables rose 161.76% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 161.76% YoY) and the FY2025 annual result came in at $651000.0, up 7.25% from the prior year.
- Receivables advanced to $1.2 million in Q1 2026 per EYPT's latest filing, from $651000.0 in the prior quarter.
- Over five years, Receivables peaked at $22.6 million in Q2 2022 and troughed at $378000.0 in Q3 2024.
- A 5-year average of $6.5 million and a median of $1.2 million in 2026 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2025: Receivables slumped 97.69% in 2023, then soared 176.46% in 2025.
- Over 5 years, Receivables stood at $15.5 million in 2022, then sank by 94.81% to $805000.0 in 2023, then decreased by 24.6% to $607000.0 in 2024, then gained by 7.25% to $651000.0 in 2025, then jumped by 77.73% to $1.2 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $1.2 million, $651000.0, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86,000.00 |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 651,000.00 |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 625,000.00 |
| Mar 31, 2025 | 442,000.00 |
| Dec 31, 2024 | 607,000.00 |
| Sep 30, 2024 | 378,000.00 |
| Jun 30, 2024 | 1.38 Mn |
| Mar 31, 2024 | 3.02 Mn |
| Dec 31, 2023 | 805,000.00 |
| Sep 30, 2023 | 483,000.00 |
| Jun 30, 2023 | 10.95 Mn |
| Mar 31, 2023 | 10.42 Mn |
| Dec 31, 2022 | 15.50 Mn |
| Sep 30, 2022 | 20.88 Mn |
| Jun 30, 2022 | 22.59 Mn |
| Mar 31, 2022 | 19.59 Mn |
| Dec 31, 2021 | 18.77 Mn |
| Sep 30, 2021 | 13.60 Mn |